However, this finding was not corroborated by subsequent data from the PYRAMID and TREAT post-marketing registries (for adalimumab and infliximab, respectively), which reported no statistically significant differences in exposure-adjusted malignancy rates—excluding lymphoma—between CD patients receiving TNFα inhibitors with or without concomitant thiopurine therapy at baseline [20,21]. Here, TNF is linked to lymphoma.